Form 4: Director David Hallal Receives Kalaris Stock Options

Director David Hallal was granted 9,000 stock options in Kalaris Therapeutics, Inc. with an exercise price of $4.72.

Summary

• Director David Hallal received a grant of 9,000 stock options for Kalaris Therapeutics, Inc. (KLRS) common stock.
• The options have an exercise price of $4.72 per share.
• The grant date for these options is June 3, 2026.
• The options are scheduled to vest in full on the earlier of June 3, 2027, or the date of the 2027 Annual Meeting of Stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The issuance of stock options results in potential future dilution for existing shareholders.

Risks

• Vesting is subject to continued service, creating a dependency on the director's ongoing tenure.

Future Outlook

The options vest in one year, contingent upon the director's continued service to the company.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practice in the biotechnology sector to incentivize long-term strategic oversight.

Comparison to Industry Standards

• The grant of stock options to non-executive directors is consistent with standard compensation packages for small-cap biotech firms.
• The one-year cliff vesting schedule is a common retention mechanism for board members.

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise of these options.

Next Steps

• Vesting of options on June 3, 2027, or the 2027 Annual Meeting of Stockholders.

Key Dates

Keywords

Kalaris Therapeutics, KLRS, Form 4, Stock Options, Insider Trading, Director Compensation